Trametinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Trametinib comprises 254 peer-reviewed publications across 15 journals, 12 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Melanoma, Histiocytosis, Langerhans-Cell, Neoplasms, and Pancreatic Neoplasms. Most recent publication: Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H., JCO Precis Oncol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Clinical features and current management experience in Gorham-Stout disease: a systematic review.
    Zhou Z, Qiu T, Zhou J, et al. · Orphanet J Rare Dis · 2025
    PubMed: PMID 40102890 · NCT07072403 · Vascular Malformations
  2. Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads.
    Thalhammer J, Jeziorski E, Marec-Bérard P, et al. · Blood · 2025
    PubMed: PMID 39486044 · NCT07022834 · Histiocytosis, Langerhans-Cell
  3. Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.
    Salama AKS, Wang V, Macrae ER, et al. · JCO Precis Oncol · 2026
    PubMed: PMID 41533998 · NCT04439292 · Multiple Myeloma
  4. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
    Ribas A, Lawrence D, Atkinson V, et al. · Nat Med · 2019
    PubMed: PMID 31171879 · NCT02130466 · Melanoma
  5. Genomic profiling informs diagnoses and treatment in vascular anomalies.
    Li D, Sheppard SE, March ME, et al. · Nat Med · 2023
    PubMed: PMID 37264205 · NCT07072403 · Vascular Malformations
  6. Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with BRAF V600E mutation-positive metastatic non-small cell lung cancer.
    Fan Y, Zhou J, Zhao Y, et al. · Transl Lung Cancer Res · 2025
    PubMed: PMID 39830765 · NCT04452877 · Carcinoma, Non-Small-Cell Lung
  7. BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology.
    Bigenwald C, Le Berichel J, Wilk CM, et al. · Nat Med · 2021
    PubMed: PMID 33958797 · NCT07022834 · Histiocytosis, Langerhans-Cell
  8. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
    Ascierto PA, Ferrucci PF, Fisher R, et al. · Nat Med · 2019
    PubMed: PMID 31171878 · NCT02130466 · Melanoma

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT01584648MelanomaProgression-Free Survival (PFS) as Assessed by the Investigator
From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)
Dabrafenib + Placebo8.8 Months
Dabrafenib + Trametinib10.2 Months
NCT01597908
COMBI-v
MelanomaOverall Survival (OS)
From the date of randomization until date of death due to any cause (up to approximately 6 years)
Dabrafenib Plus Trametinib26.0 Months
Vemurafenib17.8 Months
NCT01682083
COMBI-AD
MelanomaPercentage of Participants With Relapse-free Survival (RFS) Events
Approximately 4 years
Dabrafenib and Trametinib Combination Therapy3 Participants
Dabrafenib and Trametinib Combination Therapy229 Participants
Dabrafenib and Trametinib Combination Therapy43 Participants
Dabrafenib and Trametinib Combination Therapy163 Participants
Dabrafenib and Trametinib Placebos149 Participants
Dabrafenib and Trametinib Placebos247 Participants
Dabrafenib and Trametinib Placebos1 Participants
Dabrafenib and Trametinib Placebos35 Participants
NCT01682083
COMBI-AD
MelanomaRelapse-free Survival (RFS)
Approximately 4 years
Dabrafenib and Trametinib Combination TherapyNA Months
Dabrafenib and Trametinib Placebos16.6 Months
NCT02101788Cystadenocarcinoma, SerousProgression-free Survival (PFS)
Time from study entry to time of progression or death, an average of 7 months for arm A and 13 months for arm B
Arm A - Control Arm7.2 months
Arm B - Experimental Arm13.0 months
NCT02224781Melanoma2-year Overall Survival (OS)
assessed every 3 months if patient is < 2 years from study entry and every 6 months if patient is 2-5 years from study entry
Arm A (Immunotherapy)0.683 Proportion of participants
Arm B (BRAF Inhibitor Therapy)0.541 Proportion of participants
NCT02967692
COMBI-i
MelanomaBiomarker Cohort (Part 2): Change From Baseline in CD8+ Cells Upon Treatment With Spartalizumab in Combination With Dabrafenib and Trametinib
Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days
Part 2- Biomarker Cohort: PDR001 400 mg Q4W + Dabrafenib 150 mg BID + Trametinib 2 mg QD0.4 Percentage Marker Area (±3.22 Standard Deviation)
Part 2- Biomarker Cohort: PDR001 400 mg Q4W + Dabrafenib 150 mg BID + Trametinib 2 mg QD1.2 Percentage Marker Area (±2.43 Standard Deviation)
NCT02967692
COMBI-i
MelanomaBiomarker Cohort (Part 2): Change From Baseline in Programmed Cell Death-ligand 1 (PD-L1) Expression Upon Treatment With Spartalizumab in Combination With Dabrafenib and Trametinib
Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days
Part 2- Biomarker Cohort: PDR001 400 mg Q4W + Dabrafenib 150 mg BID + Trametinib 2 mg QD1.7 Percentage of positive tumor cells (±13.05 Standard Deviation)
Part 2- Biomarker Cohort: PDR001 400 mg Q4W + Dabrafenib 150 mg BID + Trametinib 2 mg QD2.7 Percentage of positive tumor cells (±7.63 Standard Deviation)
NCT02967692
COMBI-i
MelanomaRandomized (Part 3): Progression-Free Survival (PFS) as Per Investigator's Assessment by RECIST 1.1
Up to disease progression or death due to any cause, whichever occurs first, assessed up to 2.8 years (Part 3)
Part 3- Arm 1: PDR001 400 mg Q4W + Dabrafenib 150 mg BID + Trametinib 2 mg QD16.2 Months
Part 3- Arm 2: Placebo + Dabrafenib 150 mg BID + Trametinib 2 mg QD12.0 Months
NCT02967692
COMBI-i
MelanomaSafety Run-In (Part 1): Number of Participants With Dose Limiting Toxicities (DLTs)
Up to 8 weeks (Part 1)
Part 1- Safety run-in: PDR001 400 mg Q4W + Dabrafenib 150 mg BID + Trametinib 2 mg QD1 Participants
NCT03551626
COMBI-APlus
MelanomaComposite Rate of Pyrexia Related Events
Baseline up to 12 months
Dabrafenib+Trametinib7.6 Percentage of participants
NCT04940052—Progression Free Survival (PFS)
From randomization to first documented progression or deaths, whichever comes first, assessed up to approximately 3 years
Dabrafenib Placebo Plus Trametinib Placebo3.7 Months
Dabrafenib Plus Trametinib12.8 Months

Publications by year

2001–2026: 254 publications.

2001
1
2004
1
2005
1
2006
4
2008
3
2009
3
2010
1
2011
2
2012
6
2013
9
2014
8
2015
13
2016
12
2017
14
2018
11
2019
20
2020
20
2021
20
2022
28
2023
32
2024
23
2025
14
2026
8

Publications by indication

Melanoma (78)

  • Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
    JCO Precis Oncol · 2025 · PMID 41066729 · NCT02465060
  • Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial.
    Lancet Oncol · 2025 · PMID 40250457 · NCT01682083
  • PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
    JCO Precis Oncol · 2025 · PMID 40865033 · NCT02465060
  • Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.
    JCO Precis Oncol · 2025 · PMID 39913886 · NCT02465060
  • Mitochondrial bioenergetics and networks in melanoma: an update.
    Apoptosis · 2025 · PMID 40721981 · NCT01989585

Histiocytosis, Langerhans-Cell (44)

  • Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads.
    Blood · 2025 · PMID 39486044 · NCT07022834
  • Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis.
    Br J Haematol · 2024 · PMID 38501389 · NCT07022834
  • Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis.
    Br J Haematol · 2024 · PMID 38501390 · NCT07022834
  • Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders.
    Haematologica · 2024 · PMID 37731389 · NCT07022834
  • Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis.
    Blood Adv · 2023 · PMID 36884302 · NCT07022834

Neoplasms (44)

  • Prospective evaluation of genomics-guided off-label treatment.
    Nature · 2026 · PMID 41986720 · NCT02925234
  • Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    JCO Precis Oncol · 2026 · PMID 42018965 · NCT02693535
  • Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
    JCO Precis Oncol · 2026 · PMID 42060861 · NCT02693535
  • Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    JCO Precis Oncol · 2026 · PMID 41538762 · NCT02693535
  • Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study.
    NPJ Precis Oncol · 2025 · PMID 40610648 · NCT02693535

Pancreatic Neoplasms (23)

  • Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
    Nat Med · 2019 · PMID 30833748 · NCT03825289
  • Pancreatic cancer.
    Nat Rev Dis Primers · 2018 · PMID 27158978 · NCT03825289
  • Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary.
    J Oncol Pract · 2018 · PMID 28399382 · NCT03825289
  • Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    J Clin Oncol · 2017 · PMID 27247222 · NCT03825289
  • A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
    Invest New Drugs · 2016 · PMID 26259955 · NCT03825289

Neoplasm Metastasis (6)

  • Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.
    Semin Cancer Biol · 2025 · PMID 39863139 · NCT03878524
  • A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
    Cancer Chemother Pharmacol · 2023 · PMID 37314501 · NCT03065387
  • Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial.
    BMC Cancer · 2022 · PMID 34740331 · NCT03784014
  • Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction.
    J Exp Clin Cancer Res · 2022 · PMID 35130943 · NCT02070549
  • Feasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France Genomic Medicine 2025 plan.
    ESMO Open · 2021 · PMID 32713836 · NCT03784014

Glioma (6)

  • Cost-Effectiveness of Dabrafenib Plus Trametinib Versus Standard Chemotherapy in BRAFV600E-Mutant Pediatric Low-Grade Glioma.
    JCO Oncol Pract · 2026 · PMID 41740060 · NCT02684058
  • FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma.
    Clin Cancer Res · 2024 · PMID 37610803 · NCT02684058
  • Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.
    J Clin Oncol · 2023 · PMID 37643378 · NCT02684058
  • Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.
    N Engl J Med · 2023 · PMID 37733309 · NCT02684058
  • Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastoma.
    Pediatr Blood Cancer · 2022 · PMID 34331515 · NCT02684058

Publications by journal

Trial-results highlights

In studies involving melanoma, the combination of dabrafenib and Trametinib has been evaluated. For Progression-Free Survival (PFS) as assessed by the investigator in NCT01584648, the median was 10.2 months for the dabrafenib + trametinib arm, compared to 8.8 months for the dabrafenib + placebo arm. In NCT01597908 (COMBI-v), the median Overall Survival (OS) was 26.0 months for the dabrafenib plus Trametinib arm, and 17.8 months for the vemurafenib arm. NCT02224781 reported 2-year Overall Survival, with Arm A (Immunotherapy) showing a 0.683 proportion of participants and Arm B (BRAF Inhibitor Therapy) showing a 0.541 proportion of participants.

Further melanoma studies include NCT01682083 (COMBI-AD), where participants with Relapse-free Survival (RFS) events were reported. For the dabrafenib and Trametinib combination therapy arm, counts were 3, 229, 43, and 163 participants. For the dabrafenib and trametinib placebos arm, counts were 149 and 247 participants. For Relapse-free Survival in the same study, the median for the dabrafenib and trametinib placebos arm was 16.6 months, while the median for the combination therapy arm was not available. In NCT02967692 (COMBI-i), for the biomarker cohort (Part 2), the mean change from baseline in CD8+ cells for the PDR001 + dabrafenib + Trametinib arm was 0.4 percentage marker area and 1.2 percentage marker area. For change from baseline in PD-L1 expression in the same study and arm, the mean values were 1.7 percentage of positive tumor cells and 2.7 percentage of positive tumor cells.

For Cystadenocarcinoma, Serous, NCT02101788 evaluated Progression-free Survival (PFS). The median PFS for Arm A (Control Arm) was 7.2 months, and for Arm B (Experimental Arm) it was 13.0 months.

All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Trametinib publications (254)

2026 (8 papers)

  1. Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.
    Salama AKS, Wang V, Macrae ER, et al. · JCO Precis Oncol · 2026 · Trial result
    PubMed: PMID 41533998 · NCT04439292 · Multiple Myeloma
  2. Prospective evaluation of genomics-guided off-label treatment.
    Verkerk K, Spiekman AC, Haj Mohammad SF, et al. · Nature · 2026 · Derived
    PubMed: PMID 41986720 · NCT02925234 (DRUP) · Neoplasms
  3. Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Pisick E, Rothe M, Garrett-Mayer E, et al. · JCO Precis Oncol · 2026 · Derived
    PubMed: PMID 42018965 · NCT02693535 (TAPUR) · Neoplasms
  4. The SOS1 inhibitor BI 1701963 as monotherapy or in combination with trametinib in patients with KRAS mutation-positive solid tumors.
    Jänne PA, Johnson ML, Li J, et al. · Clin Cancer Res · 2026 · Derived
    PubMed: PMID 42048384 · NCT04111458
  5. Cost-Effectiveness of Dabrafenib Plus Trametinib Versus Standard Chemotherapy in BRAFV600E-Mutant Pediatric Low-Grade Glioma.
    Gascon B, Gauvreau C, Yang A, et al. · JCO Oncol Pract · 2026 · Derived
    PubMed: PMID 41740060 · NCT02684058 · Glioma
  6. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Cobain EF, Rothe M, Garrett-Mayer E, et al. · JCO Precis Oncol · 2026 · Derived
    PubMed: PMID 42060861 · NCT02693535 (TAPUR) · Neoplasms
  7. Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Carrizosa DR, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2026 · Derived
    PubMed: PMID 41538762 · NCT02693535 (TAPUR) · Neoplasms
  8. Lesional dosimetry in 131I refractory metastatic differentiated thyroid cancer with BRAFp.V600E or RAS mutation treated with trametinib +/- dabrafenib followed by radioactive iodine.
    Anizan N, Pignard A, Borget I, et al. · Phys Med · 2026 · Derived
    PubMed: PMID 41861727 · NCT03244956 (MERAIODE)

2025 (14 papers)

  1. Clinical features and current management experience in Gorham-Stout disease: a systematic review.
    Zhou Z, Qiu T, Zhou J, et al. · Orphanet J Rare Dis · 2025 · Trial result
    PubMed: PMID 40102890 · NCT07072403 · Vascular Malformations
  2. Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads.
    Thalhammer J, Jeziorski E, Marec-Bérard P, et al. · Blood · 2025 · Trial result
    PubMed: PMID 39486044 · NCT07022834 · Histiocytosis, Langerhans-Cell
  3. Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with BRAF V600E mutation-positive metastatic non-small cell lung cancer.
    Fan Y, Zhou J, Zhao Y, et al. · Transl Lung Cancer Res · 2025 · Trial result
    PubMed: PMID 39830765 · NCT04452877 · Carcinoma, Non-Small-Cell Lung
  4. Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
    Tsao AS, Song Z, Ho AL, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 41066729 · NCT02465060 · Melanoma
  5. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.
    Tost J, Ak-Aksoy S, Campa D, et al. · Semin Cancer Biol · 2025 · Derived
    PubMed: PMID 39863139 · NCT03878524 · Neoplasm Metastasis
  6. Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial.
    Syeda MM, Long GV, Garrett J, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 40250457 · NCT01682083 (COMBI-AD) · Melanoma
  7. Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study.
    Mangat PK, Kirkwood MK, Hinshaw DC, et al. · NPJ Precis Oncol · 2025 · Derived
    PubMed: PMID 40610648 · NCT02693535 (TAPUR) · Neoplasms
  8. PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
    Janku F, Jegede OA, Puhalla SL, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 40865033 · NCT02465060 · Melanoma
  9. Precision treatment guided by patient-derived organoids-based drug testing for locally advanced thyroid cancer: a single arm, phase 2 study.
    Guo Z, Liu J, Zhang X, et al. · Endocrine · 2025 · Derived
    PubMed: PMID 40304938 · NCT06482086
  10. Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.
    Gouda MA, Wei Z, Rodon J, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 39913886 · NCT02465060 · Melanoma
  11. Mitochondrial bioenergetics and networks in melanoma: an update.
    Giannitti G, Paganoni AJJ, Marchesi S, et al. · Apoptosis · 2025 · Derived
    PubMed: PMID 40721981 · NCT01989585 · Melanoma
  12. Trametinib as a targeted treatment in cardiac and lymphatic presentations of Noonan syndrome.
    De Brouchoven I, Lorand J, Bofferding L, et al. · Front Pediatr · 2025 · Derived
    PubMed: PMID 40041314 · NCT06555237 (MEKinRAS) · Cardiomegaly
  13. Shared molecular, cellular, and environmental hallmarks in cardiovascular disease and cancer: Any place for drug repurposing?
    Avolio E, Bassani B, Campanile M, et al. · Pharmacol Rev · 2025 · Derived
    PubMed: PMID 40148035 · NCT04258046
  14. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Al Baghdadi T, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 41100773 · NCT02693535 (TAPUR) · Neoplasms

2024 (23 papers)

  1. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis.
    Parekh D, Lin H, Batajoo A, et al. · Br J Haematol · 2024 · Trial result
    PubMed: PMID 38501389 · NCT07022834 · Histiocytosis, Langerhans-Cell
  2. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis.
    Karri V, Lin H, Velazquez J, et al. · Br J Haematol · 2024 · Trial result
    PubMed: PMID 38501390 · NCT07022834 · Histiocytosis, Langerhans-Cell
  3. Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach.
    Grynberg S, Vered M, Shapira-Frommer R, et al. · J Natl Cancer Inst · 2024 · Trial result
    PubMed: PMID 37966914 · NCT06819605 (NETCAM-RCT) · Ameloblastoma
  4. The Effect of Conservative vs. Radical Treatment of Ameloblastoma on Recurrence Rate and Quality of Life: An Umbrella Review.
    Gasparro R, Giordano F, Campana MD, et al. · J Clin Med · 2024 · Trial result
    PubMed: PMID 39274556 · NCT06819605 (NETCAM-RCT) · Ameloblastoma
  5. Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders.
    Cournoyer E, Ferrell J, Sharp S, et al. · Haematologica · 2024 · Trial result
    PubMed: PMID 37731389 · NCT07022834 · Histiocytosis, Langerhans-Cell
  6. Ophthalmologic Findings in Pediatric Erdheim-Chester Disease: A Literature Review With a Novel Case Report.
    Yeager LB, Grimes JM, Dal Col AK, et al. · Ophthalmic Plast Reconstr Surg · 2024 · Derived
    PubMed: PMID 36877575 · NCT02281760 · Histiocytosis
  7. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Worden FP, Pisick E, Rothe M, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 39413339 · NCT02693535 (TAPUR) · Neoplasms
  8. Revolutionizing cancer drug development: Harnessing the potential of basket trials.
    Subbiah V, Burris HA, Kurzrock R, et al. · Cancer · 2024 · Derived
    PubMed: PMID 37934000 · NCT02465060 · Melanoma
  9. Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group.
    Stieglitz E, Lee AG, Angus SP, et al. · Cancer Discov · 2024 · Derived
    PubMed: PMID 38867349 · NCT03190915 · Neurofibromatosis 1
  10. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Srkalovic G, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 38865672 · NCT02693535 (TAPUR) · Neoplasms
  11. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Schuetze S, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 39013131 · NCT02693535 (TAPUR) · Neoplasms
  12. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer.
    Planchard D, Wolf J, Solomon B, et al. · Lung Cancer · 2024 · Derived
    PubMed: PMID 39383771 · NCT02974725 · Melanoma
  13. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study.
    Perez JK, Kleber J, Rothe M, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 38564684 · NCT02693535 (TAPUR) · Neoplasms
  14. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
    Long GV, Hauschild A, Santinami M, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 38899716 · NCT01682083 (COMBI-AD) · Melanoma
  15. Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.
    Long GV, Carlino MS, Au-Yeung G, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 38907159 · NCT02858921 (Neo Trio) · Melanoma
  16. Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.
    Gien LT, Song Z, Poklepovic A, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 39666929 · NCT02465060 · Melanoma
  17. Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
    Geurts BS, Zeverijn LJ, Leek LVM, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 38630551 · NCT02925234 (DRUP) · Neoplasms
  18. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Cannon TL, Rothe M, Mangat PK, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38748939 · NCT02693535 (TAPUR) · Neoplasms
  19. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Calfa CJ, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 38354330 · NCT02693535 (TAPUR) · Neoplasms
  20. FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma.
    Barbato MI, Nashed J, Bradford D, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 37610803 · NCT02684058 · Glioma
  21. A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
    Algazi AP, Moon J, Lao CD, et al. · Cancer · 2024 · Derived
    PubMed: PMID 38261444 · NCT01902173 · Melanoma
  22. Vascular malformations: An overview of their molecular pathways, detection of mutational profiles and subsequent targets for drug therapy.
    Mansur A, Radovanovic I · Front Neurol · 2024 · Background
    PubMed: PMID 36846125 · NCT06098872 · Arteriovenous Malformations
  23. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial.
    Kuboki Y, Fakih M, Strickler J, et al. · Nat Med · 2024 · Background
    PubMed: PMID 38177853 · NCT04185883

2023 (32 papers)

  1. Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis.
    Whitlock JA, Geoerger B, Dunkel IJ, et al. · Blood Adv · 2023 · Trial result
    PubMed: PMID 36884302 · NCT07022834 · Histiocytosis, Langerhans-Cell
  2. Marked Improvement in Soft Tissue and CNS Manifestations of Adult Langerhans Cell Histiocytosis on Targeted MEK Inhibitor Therapy.
    Lin HT, Wikenheiser-Brokamp KA, Udstuen G, et al. · Chest · 2023 · Trial result
    PubMed: PMID 36759117 · NCT07022834 · Histiocytosis, Langerhans-Cell
  3. Genomic profiling informs diagnoses and treatment in vascular anomalies.
    Li D, Sheppard SE, March ME, et al. · Nat Med · 2023 · Trial result
    PubMed: PMID 37264205 · NCT07072403 · Vascular Malformations
  4. Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH.
    Evseev D, Osipova D, Kalinina I, et al. · Blood Adv · 2023 · Trial result
    PubMed: PMID 37216396 · NCT07022834 · Histiocytosis, Langerhans-Cell
  5. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
    Zeverijn LJ, Looze EJ, Thavaneswaran S, et al. · Int J Cancer · 2023 · Derived
    PubMed: PMID 37424386 · NCT02925234 (DRUP) · Neoplasms
  6. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.
    Yang ES, Halabi S, Rothe M, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 36753688 · NCT02693535 (TAPUR) · Neoplasms
  7. Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.
    Wisinski KB, Flamand Y, Wilson MA, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 37053535 · NCT02465060 · Melanoma
  8. Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial.
    Tian J, Chen JH, Chao SX, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 36702949 · NCT03668431 · Colorectal Neoplasms
  9. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
    Subbiah V, Kreitman RJ, Wainberg ZA, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 37059834 · NCT02034110 · Neoplasms
  10. IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.
    Rozeman EA, Versluis JM, Sikorska K, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 37479483 · NCT02625337 (IMPemBra) · Melanoma
  11. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Rohatgi N, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 38039429 · NCT02693535 (TAPUR) · Neoplasms
  12. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
    Piha-Paul SA, Tseng C, Tran HT, et al. · Cancer Chemother Pharmacol · 2023 · Derived
    PubMed: PMID 37314501 · NCT03065387 · Neoplasm Metastasis
  13. The NCI-MATCH trial: lessons for precision oncology.
    O'Dwyer PJ, Gray RJ, Flaherty KT, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 37322121 · NCT02465060 · Melanoma
  14. Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.
    Mooradian MJ, Cleary JM, Giobbie-Hurder A, et al. · Cancer · 2023 · Derived
    PubMed: PMID 37042037 · NCT02097225 · Melanoma
  15. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Meric-Bernstam F, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 38096472 · NCT02693535 (TAPUR) · Neoplasms
  16. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial.
    Mangat PK, Garrett-Mayer E, Perez JK, et al. · Clin Trials · 2023 · Derived
    PubMed: PMID 37489819 · NCT02693535 (TAPUR) · Neoplasms
  17. Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma.
    Li SN, Wan X, Peng LB, et al. · BMC Health Serv Res · 2023 · Derived
    PubMed: PMID 36653848 · NCT01682083 (COMBI-AD) · Melanoma
  18. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer.
    Leboulleux S, Benisvy D, Taieb D, et al. · Thyroid · 2023 · Derived
    PubMed: PMID 37350119 · NCT03244956 (MERAIODE)
  19. Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC.
    Lara MS, Gubens MA, Bacaltos B, et al. · JTO Clin Res Rep · 2023 · Derived
    PubMed: PMID 36545322 · NCT03087448 · Carcinoma, Non-Small-Cell Lung
  20. Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.
    Kreitman RJ, Moreau P, Ravandi F, et al. · Blood · 2023 · Derived
    PubMed: PMID 36108341 · NCT02034110 · Neoplasms
  21. Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.
    Hicks HM, Pozdeyev N, Sams SB, et al. · Mol Cancer Res · 2023 · Derived
    PubMed: PMID 37219859 · NCT02034110 · Neoplasms
  22. Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.
    Hargrave DR, Terashima K, Hara J, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 37643378 · NCT02684058 · Glioma
  23. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
    Gorry C, McCullagh L, O'Donnell H, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 36648215 · NCT02231775 · Melanoma
  24. Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
    Geurts BS, Battaglia TW, van Berge Henegouwen JM, et al. · BMC Cancer · 2023 · Derived
    PubMed: PMID 36870947 · NCT02925234 (DRUP) · Neoplasms
  25. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Ganti AK, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 37315265 · NCT02693535 (TAPUR) · Neoplasms
  26. Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042).
    Gadgeel SM, Miao J, Riess JW, et al. · Clin Cancer Res · 2023 · Derived
    PubMed: PMID 37233987 · NCT02642042 · Carcinoma, Non-Small-Cell Lung
  27. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Duvivier HL, Rothe M, Mangat PK, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 37561967 · NCT02693535 (TAPUR) · Neoplasms
  28. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
    de Braud F, Dooms C, Heist RS, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36947734 · NCT02974725 · Melanoma
  29. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.
    Bouffet E, Hansford JR, Garrè ML, et al. · N Engl J Med · 2023 · Derived
    PubMed: PMID 37733309 · NCT02684058 · Glioma
  30. Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.
    Bouffet E, Geoerger B, Moertel C, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36375115 · NCT02124772 · Neoplasms
  31. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
    Atkins MB, Lee SJ, Chmielowski B, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36166727 · NCT02224781 · Melanoma
  32. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.
    Ahn ER, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 37027810 · NCT02693535 (TAPUR) · Neoplasms

2022 (28 papers)

  1. Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial.
    Italiano A, Dinart D, Soubeyran I, et al. · BMC Cancer · 2022 · Trial result
    PubMed: PMID 34740331 · NCT03784014 (MULTISARC) · Neoplasm Metastasis
  2. Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.
    Busaidy NL, Konda B, Wei L, et al. · Thyroid · 2022 · Trial result
    PubMed: PMID 35658604 · NCT01723202 · Thyroid Neoplasms
  3. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
    Wen PY, Stein A, van den Bent M, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 34838156 · NCT02034110 · Neoplasms
  4. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
    Wang Y, Liu S, Yang Z, et al. · Cancer Cell · 2022 · Derived
    PubMed: PMID 34416167 · NCT02196181 · Melanoma
  5. Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction.
    Voon PJ, Chen EX, Chen HX, et al. · J Exp Clin Cancer Res · 2022 · Derived
    PubMed: PMID 35130943 · NCT02070549 · Neoplasm Metastasis
  6. Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.
    van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, et al. · Cancer Chemother Pharmacol · 2022 · Derived
    PubMed: PMID 35598186 · NCT02925234 (DRUP) · Neoplasms
  7. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).
    Tawbi HA, Robert C, Brase JC, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 35728875 · NCT02967692 (COMBI-i) · Melanoma
  8. Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastoma.
    Shahid S, Kushner BH, Modak S, et al. · Pediatr Blood Cancer · 2022 · Derived
    PubMed: PMID 34331515 · NCT02684058 · Glioma
  9. Platelet p110β mediates platelet-leukocyte interaction and curtails bacterial dissemination in pneumococcal pneumonia.
    Schrottmaier WC, Kral-Pointner JB, Salzmann M, et al. · Cell Rep · 2022 · Derived
    PubMed: PMID 36351402 · NCT02465060 · Melanoma
  10. Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases.
    Palmer JD, Prasad RN, Fabian D, et al. · Radiother Oncol · 2022 · Derived
    PubMed: PMID 35367525 · NCT02015117 · Brain Neoplasms
  11. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.
    Nassar KW, Hintzsche JD, Bagby SM, et al. · Mol Cancer Ther · 2022 · Derived
    PubMed: PMID 34376578 · NCT02645149 (Match Mel) · Melanoma
  12. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
    Nakauma-González JA, Rijnders M, van Riet J, et al. · Eur Urol · 2022 · Derived
    PubMed: PMID 35086719 · NCT02925234 (DRUP) · Neoplasms
  13. War against NRAS-Mutant Melanoma Using Targeted Therapies Remains Challenging.
    Moschos SJ · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 35587446 · NCT04417621 · Melanoma
  14. Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial.
    Mao L, Ding Y, Bai X, et al. · Front Oncol · 2022 · Derived
    PubMed: PMID 34504796 · NCT02083354 · Melanoma
  15. KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.
    Maio M, Carlino MS, Joshua AM, et al. · Eur J Cancer · 2022 · Derived
    PubMed: PMID 34801354 · NCT02130466 · Melanoma
  16. The TAZ-CAMTA1 Fusion Protein Promotes Tumorigenesis via Connective Tissue Growth Factor and Ras-MAPK Signaling in Epithelioid Hemangioendothelioma.
    Ma S, Kanai R, Pobbati AV, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 35443056 · NCT03148275 · Hemangioendothelioma, Epithelioid
  17. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.
    Krop IE, Jegede OA, Grilley-Olson JE, et al. · JCO Precis Oncol · 2022 · Derived
    PubMed: PMID 35138919 · NCT02465060 · Melanoma
  18. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Johnson B, Haymaker CL, Parra ER, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 36007963 · NCT03428126 · Colorectal Neoplasms
  19. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.
    Gupta R, Meric-Bernstam F, Rothe M, et al. · JCO Precis Oncol · 2022 · Derived
    PubMed: PMID 36315917 · NCT02693535 (TAPUR) · Neoplasms
  20. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
    Gershenson DM, Miller A, Brady WE, et al. · Lancet · 2022 · Derived
    PubMed: PMID 35123694 · NCT02101788 · Cystadenocarcinoma, Serous
  21. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
    Dummer R, Long GV, Robert C, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35030011 · NCT02967692 (COMBI-i) · Melanoma
  22. Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
    Damodaran S, Zhao F, Deming DA, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35133871 · NCT02465060 · Melanoma
  23. A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer.
    Chuang J, Gong J, Li SM, et al. · Clin Colorectal Cancer · 2022 · Derived
    PubMed: PMID 35738999 · NCT03317119 · Colorectal Neoplasms
  24. Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus.
    Atkinson V, Robert C, Grob JJ, et al. · Eur J Cancer · 2022 · Derived
    PubMed: PMID 35042070 · NCT03551626 (COMBI-APlus) · Melanoma
  25. Clinical trial results show promise of targeting autophagy BRAF mutant melanoma.
    Amaravadi RK · Autophagy · 2022 · Derived
    PubMed: PMID 35156519 · NCT02257424 (BAMM)
  26. Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer.
    Alshammari K, Aung KL, Zhang T, et al. · Clin Colorectal Cancer · 2022 · Derived
    PubMed: PMID 34417144 · NCT02399943 · Colorectal Neoplasms
  27. Classification of Vascular Anomalies: An Update.
    Steiner JE, Drolet BA · Semin Intervent Radiol · 2022 · Background
    PubMed: PMID 28955111 · NCT04258046
  28. Successful management of an arteriovenous malformation with trametinib in a patient with capillary-malformation arteriovenous malformation syndrome and cardiac compromise.
    Nicholson CL, Flanagan S, Murati M, et al. · Pediatr Dermatol · 2022 · Background
    PubMed: PMID 35014097 · NCT06098872 · Arteriovenous Malformations

2021 (20 papers)

  1. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.
    Salama AKS, Li S, Macrae ER, et al. · J Clin Oncol · 2021 · Trial result
    PubMed: PMID 32758030 · NCT04439292 · Multiple Myeloma
  2. Kaposiform lymphangiomatosis effectively treated with MEK inhibition.
    Foster JB, Li D, March ME, et al. · EMBO Mol Med · 2021 · Trial result
    PubMed: PMID 32894644 · NCT07072403 · Vascular Malformations
  3. Feasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France Genomic Medicine 2025 plan.
    FGM 2025 Workflow Study Group (Alliance nationale des Sciences de la Vie et de la Santé), Auzanneau C, Bacq D, et al. · ESMO Open · 2021 · Trial result
    PubMed: PMID 32713836 · NCT03784014 (MULTISARC) · Neoplasm Metastasis
  4. BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology.
    Bigenwald C, Le Berichel J, Wilk CM, et al. · Nat Med · 2021 · Trial result
    PubMed: PMID 33958797 · NCT07022834 · Histiocytosis, Langerhans-Cell
  5. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
    Syeda MM, Wiggins JM, Corless BC, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 33587894 · NCT02039947 · Melanoma
  6. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.
    Schadendorf D, Robert C, Dummer R, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 34225229 · NCT01597908 (COMBI-v) · Melanoma
  7. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study.
    Nebhan CA, Johnson DB, Sullivan RJ, et al. · Oncologist · 2021 · Derived
    PubMed: PMID 33861486 · NCT02296112 · Melanoma
  8. Treatment advances for pediatric and adult onset neoplasms with monocytosis.
    McCullough KB, Kuhn AK, Patnaik MM, et al. · Curr Hematol Malig Rep · 2021 · Derived
    PubMed: PMID 33728588 · NCT03190915 · Neurofibromatosis 1
  9. A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer.
    Kim R, Tan E, Wang E, et al. · Oncologist · 2021 · Derived
    PubMed: PMID 32776632 · NCT02292173 · Digestive System Diseases
  10. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
    Flaherty KT, Gray RJ, Chen AP, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33048619 · NCT02465060 · Melanoma
  11. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Fisher JG, Tait D, Garrett-Mayer E, et al. · Target Oncol · 2021 · Derived
    PubMed: PMID 33090333 · NCT02693535 (TAPUR) · Neoplasms
  12. Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma.
    Dalton KM, Lochmann TL, Floros KV, et al. · Proc Natl Acad Sci U S A · 2021 · Derived
    PubMed: PMID 33762304 · NCT03026517 · Melanoma
  13. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
    Chae YK, Hong F, Vaklavas C, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 32463741 · NCT02465060 · Melanoma
  14. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Alva AS, Mangat PK, Garrett-Mayer E, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33844595 · NCT02693535 (TAPUR) · Neoplasms
  15. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Al Baghdadi T, Garrett-Mayer E, Halabi S, et al. · Target Oncol · 2021 · Derived
    PubMed: PMID 33068284 · NCT02693535 (TAPUR) · Neoplasms
  16. Comment on: Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.
    Vicenzi P, Ray A · Pediatr Blood Cancer · 2021 · Background
    PubMed: PMID 33089615 · NCT06582745 · Histiocytosis, Langerhans-Cell
  17. Response to trametinib treatment in progressive pediatric low-grade glioma patients.
    Selt F, van Tilburg CM, Bison B, et al. · J Neurooncol · 2021 · Background
    PubMed: PMID 33026636 · NCT06582745 · Histiocytosis, Langerhans-Cell
  18. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement.
    Jouenne F, Chevret S, Bugnet E, et al. · Eur Respir J · 2021 · Background
    PubMed: PMID 31806714 · NCT06582745 · Histiocytosis, Langerhans-Cell
  19. Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling.
    Fish JE, Flores Suarez CP, Boudreau E, et al. · Circ Res · 2021 · Background
    PubMed: PMID 32552404 · NCT06098872 · Arteriovenous Malformations
  20. Response to trametinib of histiocytosis with an activating PTPN11 mutation.
    Farnault L, Hélias-Rodzewicz Z, Venton G, et al. · Leuk Lymphoma · 2021 · Background
    PubMed: PMID 31393194 · NCT04943224 (TRAM) · Histiocytosis, Langerhans-Cell

2020 (20 papers)

  1. Langerhans cell histiocytosis.
    Rodriguez-Galindo C, Allen CE · Blood · 2020 · Trial result
    PubMed: PMID 32106306 · NCT07022834 · Histiocytosis, Langerhans-Cell
  2. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.
    Donadieu J, Larabi IA, Tardieu M, et al. · J Clin Oncol · 2020 · Trial result
    PubMed: PMID 31513482 · NCT07022834 · Histiocytosis, Langerhans-Cell
  3. A somatic activating NRAS variant associated with kaposiform lymphangiomatosis.
    Barclay SF, Inman KW, Luks VL, et al. · Genet Med · 2020 · Trial result
    PubMed: PMID 30542204 · NCT07072403 · Vascular Malformations
  4. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
    Subbiah V, Lassen U, Élez E, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 32818466 · NCT02034110 · Neoplasms
  5. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
    Si L, Zhang X, Shin SJ, et al. · Eur J Cancer · 2020 · Derived
    PubMed: PMID 32534242 · NCT02083354 · Melanoma
  6. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.
    Schadendorf D, Hauschild A, Santinami M, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 30928620 · NCT01682083 (COMBI-AD) · Melanoma
  7. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.
    Ribas A, Algazi A, Ascierto PA, et al. · Nat Commun · 2020 · Derived
    PubMed: PMID 33288749 · NCT02027961 · Melanoma
  8. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
    Perreault S, Larouche V, Tabori U, et al. · BMC Cancer · 2020 · Derived
    PubMed: PMID 31881853 · NCT03363217 · Glioma
  9. KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.
    Owen DH, Konda B, Sipos J, et al. · J Natl Compr Canc Netw · 2020 · Derived
    PubMed: PMID 31085763 · NCT01723202 · Thyroid Neoplasms
  10. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.
    Long GV, Saw RPM, Lo S, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 31171444 · NCT01972347 (Neo Combi) · Melanoma
  11. Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia.
    Kim HY, Duong JK, Gonzalez M, et al. · Cancer Chemother Pharmacol · 2020 · Derived
    PubMed: PMID 30661097 · NCT01972347 (Neo Combi) · Melanoma
  12. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.
    Hauschild A, Dummer R, Schadendorf D, et al. · J Clin Oncol · 2020 · Derived
    PubMed: PMID 30343620 · NCT01682083 (COMBI-AD) · Melanoma
  13. Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.
    Erba HP, Becker PS, Shami PJ, et al. · Blood Adv · 2020 · Derived
    PubMed: PMID 31253596 · NCT02016729 · Neoplasms
  14. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
    Dummer R, Lebbé C, Atkinson V, et al. · Nat Med · 2020 · Derived
    PubMed: PMID 33020648 · NCT02967692 (COMBI-i) · Melanoma
  15. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
    Dummer R, Hauschild A, Santinami M, et al. · N Engl J Med · 2020 · Derived
    PubMed: PMID 32877599 · NCT01682083 (COMBI-AD) · Melanoma
  16. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
    Dummer R, Brase JC, Garrett J, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 32007138 · NCT01682083 (COMBI-AD) · Melanoma
  17. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
    Algazi AP, Othus M, Daud AI, et al. · Nat Med · 2020 · Derived
    PubMed: PMID 33020646 · NCT02196181 · Melanoma
  18. A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.
    Mak G, Soria JC, Blagden SP, et al. · Br J Cancer · 2020 · Background
    PubMed: PMID 30992546 · NCT01938443 · Neoplasms
  19. Intramuscular fast-flow vascular anomaly contains somatic MAP2K1 and KRAS mutations.
    Goss JA, Konczyk DJ, Smits PJ, et al. · Angiogenesis · 2020 · Background
    PubMed: PMID 31486960 · NCT04258046
  20. Monitoring Arteriovenous Malformation Response to Genotype-Targeted Therapy.
    Edwards EA, Phelps AS, Cooke D, et al. · Pediatrics · 2020 · Background
    PubMed: PMID 32859736 · NCT06098872 · Arteriovenous Malformations

2019 (20 papers)

  1. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
    Ribas A, Lawrence D, Atkinson V, et al. · Nat Med · 2019 · Trial result
    PubMed: PMID 31171879 · NCT02130466 · Melanoma
  2. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions.
    Hogstad B, Berres ML, Chakraborty R, et al. · J Exp Med · 2019 · Trial result
    PubMed: PMID 29263218 · NCT07022834 · Histiocytosis, Langerhans-Cell
  3. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
    Ascierto PA, Ferrucci PF, Fisher R, et al. · Nat Med · 2019 · Trial result
    PubMed: PMID 31171878 · NCT02130466 · Melanoma
  4. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
    Algazi AP, Esteve-Puig R, Nosrati A, et al. · Pigment Cell Melanoma Res · 2019 · Trial result
    PubMed: PMID 28921907 · NCT01941927 · Melanoma
  5. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
    Subbiah V, Kreitman RJ, Wainberg ZA, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29072975 · NCT02034110 · Neoplasms
  6. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    Robert C, Grob JJ, Stroyakovskiy D, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 31166680 · NCT01584648 · Melanoma
  7. Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data.
    Li J, Sasane M, Zhang J, et al. · BMJ Open · 2019 · Derived
    PubMed: PMID 30121602 · NCT01336634 · Neoplasms
  8. New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma.
    Barker CA, Salama AK · J Natl Compr Canc Netw · 2019 · Derived
    PubMed: PMID 29784747 · NCT02224781 · Melanoma
  9. Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure.
    Barbie DA, Spira A, Kelly K, et al. · Clin Lung Cancer · 2019 · Derived
    PubMed: PMID 30087028 · NCT02258607
  10. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN, Prieto PA, Tetzlaff MT, et al. · Lancet Oncol · 2019 · Derived
    PubMed: PMID 29361468 · NCT02231775 · Melanoma
  11. Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a MAP2K1 Deletion.
    Lorillon G, Jouenne F, Baroudjian B, et al. · Am J Respir Crit Care Med · 2019 · Background
    PubMed: PMID 29694792 · NCT04943224 (TRAM) · Histiocytosis, Langerhans-Cell
  12. Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.
    Lian T, Li C, Wang H, et al. · Cancer Treat Rev · 2019 · Background
    PubMed: PMID 31715422 · NCT04943224 (TRAM) · Histiocytosis, Langerhans-Cell
  13. Genotype-Guided Medical Treatment of an Arteriovenous Malformation in a Child.
    Lekwuttikarn R, Lim YH, Admani S, et al. · JAMA Dermatol · 2019 · Background
    PubMed: PMID 30566190 · NCT04258046
  14. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
    Kinsey CG, Camolotto SA, Boespflug AM, et al. · Nat Med · 2019 · Background
    PubMed: PMID 30833748 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  15. Is There Value in Molecular Profiling of Soft-Tissue Sarcoma?
    Italiano A · Curr Treat Options Oncol · 2019 · Background
    PubMed: PMID 30523434 · NCT03784014 (MULTISARC) · Neoplasm Metastasis
  16. High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations.
    Hong T, Yan Y, Li J, et al. · Brain · 2019 · Background
    PubMed: PMID 30544177 · NCT06098872 · Arteriovenous Malformations
  17. Study of Molecular Mechanism of the Interaction Between MEK1/2 and Trametinib with Docking and Molecular Dynamic Simulation.
    Hashemzadeh S, Ramezani F, Rafii-Tabar H, et al. · Interdiscip Sci · 2019 · Background
    PubMed: PMID 30465279 · NCT04258046
  18. Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition.
    Eckstein OS, Visser J, Rodriguez-Galindo C, et al. · Blood · 2019 · Background
    PubMed: PMID 30718231 · NCT06582745 · Histiocytosis, Langerhans-Cell
  19. Efficacy of MEK inhibition in patients with histiocytic neoplasms.
    Diamond EL, Durham BH, Ulaner GA, et al. · Nature · 2019 · Background
    PubMed: PMID 30867592 · NCT06582745 · Histiocytosis, Langerhans-Cell
  20. Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter?
    Crombag MBS, van Doremalen JGC, Janssen JM, et al. · Br J Clin Pharmacol · 2019 · Background
    PubMed: PMID 30068020 · NCT04943224 (TRAM) · Histiocytosis, Langerhans-Cell

2018 (11 papers)

  1. Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.
    Martín Algarra S, Soriano V, Fernández-Morales L, et al. · Medicine (Baltimore) · 2018 · Trial result
    PubMed: PMID 29384960 · NCT02439411 (DEIS) · Melanoma
  2. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis.
    Patel KR, Chowdhary M, Switchenko JM, et al. · Melanoma Res · 2018 · Derived
    PubMed: PMID 27223498 · NCT01721603 · Melanoma
  3. Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine.
    Ikeda M, Ioka T, Fukutomi A, et al. · Cancer Sci · 2018 · Derived
    PubMed: PMID 29121415 · NCT01943864 · Neoplasms
  4. Trametinib (GSK1120212).
    Zeiser R, Andrlová H, Meiss F, et al. · Recent Results Cancer Res · 2018 · Background
    PubMed: PMID 30069762 · NCT04258046
  5. Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain.
    Nikolaev SI, Fish JE, Radovanovic I, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29669234 · NCT06098872 · Arteriovenous Malformations
  6. Pancreatic cancer.
    Kleeff J, Korc M, Apte M, et al. · Nat Rev Dis Primers · 2018 · Background
    PubMed: PMID 27158978 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  7. Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.
    Herbrink M, de Vries N, Rosing H, et al. · Biomed Chromatogr · 2018 · Background
    PubMed: PMID 29165815 · NCT04943224 (TRAM) · Histiocytosis, Langerhans-Cell
  8. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors.
    Cox DS, Allred A, Zhou Y, et al. · Clin Pharmacol Drug Dev · 2018 · Background
    PubMed: PMID 27136909 · NCT04943224 (TRAM) · Histiocytosis, Langerhans-Cell
  9. Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
    Cardoso E, Mercier T, Wagner AD, et al. · J Chromatogr B Analyt Technol Biomed Life Sci · 2018 · Background
    PubMed: PMID 29544202 · NCT04943224 (TRAM) · Histiocytosis, Langerhans-Cell
  10. Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary.
    Balaban EP, Mangu PB, Yee NS, et al. · J Oncol Pract · 2018 · Background
    PubMed: PMID 28399382 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  11. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.
    Andtbacka RH, Ross M, Puzanov I, et al. · Ann Surg Oncol · 2018 · Background
    PubMed: PMID 27342831 · NCT03972046 · Melanoma

2017 (14 papers)

  1. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.
    Schreuer M, Jansen Y, Planken S, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28268064 · NCT02296996 · Melanoma
  2. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
    Planchard D, Smit EF, Groen HJM, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28919011 · NCT01336634 · Neoplasms
  3. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
    Planchard D, Kim TM, Mazieres J, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27080216 · NCT01336634 · Neoplasms
  4. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
    Planchard D, Besse B, Groen HJM, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27283860 · NCT01336634 · Neoplasms
  5. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV, Hauschild A, Santinami M, et al. · N Engl J Med · 2017 · Derived
    PubMed: PMID 28891408 · NCT01682083 (COMBI-AD) · Melanoma
  6. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
    Long GV, Grob JJ, Nathan P, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27864013 · NCT01584648 · Melanoma
  7. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.
    Gandara DR, Leighl N, Delord JP, et al. · J Thorac Oncol · 2017 · Derived
    PubMed: PMID 27876675 · NCT01192165 · Neoplasms
  8. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
    Davies MA, Saiag P, Robert C, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28592387 · NCT02039947 · Melanoma
  9. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Sohal DP, Mangu PB, Khorana AA, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 27247222 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  10. Cancer Statistics, 2017.
    Siegel RL, Miller KD, Jemal A, et al. · CA Cancer J Clin · 2017 · Background
    PubMed: PMID 28055103 · NCT03972046 · Melanoma
  11. RECIST 1.1-Update and clarification: From the RECIST committee.
    Schwartz LH, Litière S, de Vries E, et al. · Eur J Cancer · 2017 · Background
    PubMed: PMID 27189322 · NCT06582745 · Histiocytosis, Langerhans-Cell
  12. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.
    Grigg C, Blake Z, Gartrell R, et al. · Semin Oncol · 2017 · Background
    PubMed: PMID 28061981 · NCT03972046 · Melanoma
  13. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R, Schadendorf D, Ascierto PA, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 28284557 · NCT04059224 (TraMel-WT) · Melanoma
  14. Somatic MAP2K1 Mutations Are Associated with Extracranial Arteriovenous Malformation.
    Couto JA, Huang AY, Konczyk DJ, et al. · Am J Hum Genet · 2017 · Background
    PubMed: PMID 28190454 · NCT04258046

2016 (12 papers)

  1. Is the NCI MATCH trial a match for gynecologic oncology?
    Moore KN, Mannel RS · Gynecol Oncol · 2016 · Derived
    PubMed: PMID 26586415 · NCT02465060 · Melanoma
  2. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.
    Menzies AM, Ashworth MT, Swann S, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 25411413 · NCT01584648 · Melanoma
  3. Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.
    Lih CJ, Sims DJ, Harrington RD, et al. · J Mol Diagn · 2016 · Derived
    PubMed: PMID 26602013 · NCT01827384
  4. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.
    Lee EQ, Ruland S, LeBoeuf NR, et al. · J Clin Oncol · 2016 · Derived
    PubMed: PMID 25092772 · NCT02034110 · Neoplasms
  5. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ, Amonkar MM, Karaszewska B, et al. · Lancet Oncol · 2016 · Derived
    PubMed: PMID 26433819 · NCT01597908 (COMBI-v) · Melanoma
  6. Years of life lost due to metastatic melanoma in 12 countries.
    Thiam A, Zhao Z, Quinn C, et al. · J Med Econ · 2016 · Background
    PubMed: PMID 26531249 · NCT03972046 · Melanoma
  7. Early Diagnosis and Monitoring of Neurodegenerative Langerhans Cell Histiocytosis.
    Sieni E, Barba C, Mortilla M, et al. · PLoS One · 2016 · Background
    PubMed: PMID 26176859 · NCT06582745 · Histiocytosis, Langerhans-Cell
  8. Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma.
    Ouellet D, Kassir N, Chiu J, et al. · Cancer Chemother Pharmacol · 2016 · Background
    PubMed: PMID 26940938 · NCT04943224 (TRAM) · Histiocytosis, Langerhans-Cell
  9. A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
    Kasuga A, Nakagawa K, Nagashima F, et al. · Invest New Drugs · 2016 · Background
    PubMed: PMID 26259955 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  10. Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
    Coit DG, Thompson JA, Algazi A, et al. · J Natl Compr Canc Netw · 2016 · Background
    PubMed: PMID 27059193 · NCT03972046 · Melanoma
  11. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    Andtbacka RH, Kaufman HL, Collichio F, et al. · J Clin Oncol · 2016 · Background
    PubMed: PMID 26014293 · NCT03972046 · Melanoma
  12. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies.
    Adams DM, Trenor CC, Hammill AM, et al. · Pediatrics · 2016 · Background
    PubMed: PMID 26783326 · NCT04258046

2015 (13 papers)

  1. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.
    Johnson AS, Crandall H, Dahlman K, et al. · J Am Coll Surg · 2015 · Trial result
    PubMed: PMID 25797743 · NCT01701037 · Melanoma
  2. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.
    Donadieu J, Bernard F, van Noesel M, et al. · Blood · 2015 · Trial result
    PubMed: PMID 26194764 · NCT07022834 · Histiocytosis, Langerhans-Cell
  3. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
    Schadendorf D, Amonkar MM, Stroyakovskiy D, et al. · Eur J Cancer · 2015 · Derived
    PubMed: PMID 25794603 · NCT01584648 · Melanoma
  4. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C, Karaszewska B, Schachter J, et al. · N Engl J Med · 2015 · Derived
    PubMed: PMID 25399551 · NCT01597908 (COMBI-v) · Melanoma
  5. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
    Long GV, Stroyakovskiy D, Gogas H, et al. · Lancet · 2015 · Derived
    PubMed: PMID 26037941 · NCT01584648 · Melanoma
  6. BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib.
    Ranzani M, Alifrangis C, Perna D, et al. · Pigment Cell Melanoma Res · 2015 · Background
    PubMed: PMID 25243813 · NCT04059224 (TraMel-WT) · Melanoma
  7. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.
    Nelson DS, van Halteren A, Quispel WT, et al. · Genes Chromosomes Cancer · 2015 · Background
    PubMed: PMID 25899310 · NCT04943224 (TRAM) · Histiocytosis, Langerhans-Cell
  8. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.
    Lyman GH, Bohlke K, Khorana AA, et al. · J Clin Oncol · 2015 · Background
    PubMed: PMID 25605844 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  9. Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH.
    Khorana AA, Otten HM, Zwicker JI, et al. · J Thromb Haemost · 2015 · Background
    PubMed: PMID 25208230 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  10. Addressing the challenges of pancreatic cancer: future directions for improving outcomes.
    Hidalgo M, Cascinu S, Kleeff J, et al. · Pancreatology · 2015 · Background
    PubMed: PMID 25547205 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  11. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
    Haroche J, Cohen-Aubart F, Emile JF, et al. · J Clin Oncol · 2015 · Background
    PubMed: PMID 25422482 · NCT06582745 · Histiocytosis, Langerhans-Cell
  12. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
    Chakraborty R, Hampton OA, Shen X, et al. · Blood · 2015 · Background
    PubMed: PMID 25202140 · NCT06582745 · Histiocytosis, Langerhans-Cell
  13. How I treat Langerhans cell histiocytosis.
    Allen CE, Ladisch S, McClain KL, et al. · Blood · 2015 · Background
    PubMed: PMID 25827831 · NCT06582745 · Histiocytosis, Langerhans-Cell

2014 (8 papers)

  1. Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly.
    Croteau SE, Kozakewich HP, Perez-Atayde AR, et al. · J Pediatr · 2014 · Trial result
    PubMed: PMID 24252784 · NCT07072403 · Vascular Malformations
  2. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
    Long GV, Stroyakovskiy D, Gogas H, et al. · N Engl J Med · 2014 · Derived
    PubMed: PMID 25265492 · NCT01584648 · Melanoma
  3. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
    Ackerman A, Klein O, McDermott DF, et al. · Cancer · 2014 · Derived
    PubMed: PMID 24577748 · NCT01767454 · Melanoma
  4. Trametinib: first global approval.
    Wright CJ, McCormack PL · Drugs · 2014 · Background
    PubMed: PMID 23846731 · NCT04258046
  5. Prevalence of venous thromboembolism at diagnosis of upper gastrointestinal cancer.
    Larsen AC, Dabrowski T, Frøkjær JB, et al. · Br J Surg · 2014 · Background
    PubMed: PMID 24446107 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  6. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
    Infante JR, Somer BG, Park JO, et al. · Eur J Cancer · 2014 · Background
    PubMed: PMID 24915778 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  7. Erdheim-Chester disease.
    Haroche J, Arnaud L, Cohen-Aubart F, et al. · Curr Rheumatol Rep · 2014 · Background
    PubMed: PMID 24532298 · NCT02281760 · Histiocytosis
  8. Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases.
    Green JS, Norris DA, Wisell J, et al. · Br J Dermatol · 2014 · Background
    PubMed: PMID 23413975 · NCT04258046

2013 (9 papers)

  1. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
    Gadner H, Minkov M, Grois N, et al. · Blood · 2013 · Trial result
    PubMed: PMID 23589673 · NCT07022834 · Histiocytosis, Langerhans-Cell
  2. Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis.
    Abraham A, Alsultan A, Jeng M, et al. · Pediatr Blood Cancer · 2013 · Trial result
    PubMed: PMID 23255383 · NCT07022834 · Histiocytosis, Langerhans-Cell
  3. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
    Kim KB, Kefford R, Pavlick AC, et al. · J Clin Oncol · 2013 · Background
    PubMed: PMID 23248257 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  4. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States.
    Khorana AA, Dalal M, Lin J, et al. · Cancer · 2013 · Background
    PubMed: PMID 22893596 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  5. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
    Haroche J, Cohen-Aubart F, Emile JF, et al. · Blood · 2013 · Background
    PubMed: PMID 23258922 · NCT02281760 · Histiocytosis
  6. Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity.
    Gysin S, Paquette J, McMahon M, et al. · Mol Cancer Res · 2013 · Background
    PubMed: PMID 22833572 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  7. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.
    Collisson EA, Trejo CL, Silva JM, et al. · Cancer Discov · 2013 · Background
    PubMed: PMID 22628411 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  8. Pathogenesis of Langerhans cell histiocytosis.
    Badalian-Very G, Vergilio JA, Fleming M, et al. · Annu Rev Pathol · 2013 · Background
    PubMed: PMID 22906202 · NCT06582745 · Histiocytosis, Langerhans-Cell
  9. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
    Awasthi N, Zhang C, Schwarz AM, et al. · Carcinogenesis · 2013 · Background
    PubMed: PMID 23803690 · NCT03825289 (THREAD) · Pancreatic Neoplasms

2012 (6 papers)

  1. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.
    Maraveyas A, Waters J, Roy R, et al. · Eur J Cancer · 2012 · Background
    PubMed: PMID 22100906 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  2. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
    Infante JR, Fecher LA, Falchook GS, et al. · Lancet Oncol · 2012 · Background
    PubMed: PMID 22805291 · NCT04943224 (TRAM) · Histiocytosis, Langerhans-Cell
  3. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
    Hauschild A, Grob JJ, Demidov LV, et al. · Lancet · 2012 · Background
    PubMed: PMID 22735384 · NCT03972046 · Melanoma
  4. Improved survival with MEK inhibition in BRAF-mutated melanoma.
    Flaherty KT, Robert C, Hersey P, et al. · N Engl J Med · 2012 · Background
    PubMed: PMID 22663011 · NCT06582745 · Histiocytosis, Langerhans-Cell
  5. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
    Flaherty KT, Infante JR, Daud A, et al. · N Engl J Med · 2012 · Background
    PubMed: PMID 23020132 · NCT03972046 · Melanoma
  6. Langerhans cell histiocytosis with refractory central nervous system involvement responsive to infliximab.
    Chohan G, Barnett Y, Gibson J, et al. · J Neurol Neurosurg Psychiatry · 2012 · Background
    PubMed: PMID 21856693 · NCT06582745 · Histiocytosis, Langerhans-Cell

2011 (2 papers)

  1. Resistance to BRAF inhibition in melanomas.
    Solit DB, Rosen N · N Engl J Med · 2011 · Background
    PubMed: PMID 21345109 · NCT03972046 · Melanoma
  2. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis.
    Lyman GH · Cancer · 2011 · Background
    PubMed: PMID 21425133 · NCT03825289 (THREAD) · Pancreatic Neoplasms

2010 (1 paper)

  1. Extracranial arteriovenous malformations: natural progression and recurrence after treatment.
    Liu AS, Mulliken JB, Zurakowski D, et al. · Plast Reconstr Surg · 2010 · Background
    PubMed: PMID 20335868 · NCT04258046

2009 (3 papers)

  1. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
    Weitzman S, Braier J, Donadieu J, et al. · Pediatr Blood Cancer · 2009 · Trial result
    PubMed: PMID 19731321 · NCT07022834 · Histiocytosis, Langerhans-Cell
  2. Ras signaling and therapies.
    Young A, Lyons J, Miller AL, et al. · Adv Cancer Res · 2009 · Background
    PubMed: PMID 19595305 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  3. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.
    Harris PA, Taylor R, Thielke R, et al. · J Biomed Inform · 2009 · Background
    PubMed: PMID 18929686 · NCT06582745 · Histiocytosis, Langerhans-Cell

2008 (3 papers)

  1. Clofarabine in refractory Langerhans cell histiocytosis.
    Rodriguez-Galindo C, Jeng M, Khuu P, et al. · Pediatr Blood Cancer · 2008 · Trial result
    PubMed: PMID 18623218 · NCT07022834 · Histiocytosis, Langerhans-Cell
  2. Incidence of Langerhans cell histiocytosis in children: a population-based study.
    Stålemark H, Laurencikas E, Karis J, et al. · Pediatr Blood Cancer · 2008 · Background
    PubMed: PMID 18266220 · NCT06582745 · Histiocytosis, Langerhans-Cell
  3. Development and validation of a predictive model for chemotherapy-associated thrombosis.
    Khorana AA, Kuderer NM, Culakova E, et al. · Blood · 2008 · Background
    PubMed: PMID 18216292 · NCT03825289 (THREAD) · Pancreatic Neoplasms

2006 (4 papers)

  1. Cancer targets in the Ras pathway.
    Rodriguez-Viciana P, Tetsu O, Oda K, et al. · Cold Spring Harb Symp Quant Biol · 2006 · Background
    PubMed: PMID 16869784 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  2. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study.
    Morimoto A, Ikushima S, Kinugawa N, et al. · Cancer · 2006 · Background
    PubMed: PMID 16804933 · NCT06582745 · Histiocytosis, Langerhans-Cell
  3. Incidence of venous thromboembolism and its effect on survival among patients with common cancers.
    Chew HK, Wun T, Harvey D, et al. · Arch Intern Med · 2006 · Background
    PubMed: PMID 16505267 · NCT03825289 (THREAD) · Pancreatic Neoplasms
  4. High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients.
    Blom JW, Osanto S, Rosendaal FR, et al. · Eur J Cancer · 2006 · Background
    PubMed: PMID 16321518 · NCT03825289 (THREAD) · Pancreatic Neoplasms

2005 (1 paper)

  1. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S, Lee SH, Dean NM, et al. · Cancer Res · 2005 · Background
    PubMed: PMID 15930308 · NCT03825289 (THREAD) · Pancreatic Neoplasms

2004 (1 paper)

  1. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group.
    Haupt R, Nanduri V, Calevo MG, et al. · Pediatr Blood Cancer · 2004 · Trial result
    PubMed: PMID 15049016 · NCT07022834 · Histiocytosis, Langerhans-Cell

2001 (1 paper)

  1. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study.
    Titgemeyer C, Grois N, Minkov M, et al. · Med Pediatr Oncol · 2001 · Background
    PubMed: PMID 11496348 · NCT06582745 · Histiocytosis, Langerhans-Cell

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).